MPM Capital

What is MPM Capital?

MPM Capital is a venture capital firm that specializes in the discovery and development of biotechnology, health care, and medical device sectors. With a focus on creating and investing in biotech companies, MPM Capital leverages its expertise to develop life-saving drugs for patients.

Their investment vision includes supporting both private and public companies, providing a comprehensive perspective on drug development throughout the industry. With more than 30 years of experience in biotech investing and being responsible for 59 FDA-approved drugs, they have a proven track record of success.

Since 2010, MPM Capital has been instrumental in founding over 40 companies through its MPM BioImpact strategy, focused on company creation and spearheading innovations in the medical field.

They have built noteworthy companies like Orna Therapeutics, which is advancing circular RNA medicines; Aktis Oncology that specializes in alpha radio-pharmaceuticals for solid tumors; ElevateBio, which powers cell, gene, and RNA therapies with integrated manufacturing and technology; and NextPoint Therapeutics that targets a novel axis in cancer biology.

The investment team at MPM Capital comprises professionals with extensive backgrounds in research, drug development, company creation, corporate strategy, and commercialization.

They collaborate with entrepreneur partners who offer domain expertise and have a shared commitment to transforming scientific discoveries into therapies that address unmet medical needs. MPM Capital's investment approximately ranges from a minimum of $1,000,000 to a maximum of $150,000,000, with a sweet spot of around $25,000,000. Their specialities include Seed, Series A, Series B, and Pre-seed investments.

With assets under management of about $100,000,000, MPM Capital continues to be a leading VC type investor in the USA with a significant impact on the healthcare and biotech landscape.